Objective--In angiogenesis, circulating mononuclear cells are recruited to vascular lesions; however, the underlying mechanisms are poorly understood. Approach and Results--Here, we characterize the functional role of protein tyrosine kinase 7 (PTK7)-expressing CD11b + mononuclear cells in vitro and in vivo using a mouse model of angiogenesis. Although the frequencies of PTK7 + CD11b + cells in the bone marrow remained similar after vascular endothelial growth factor-A-induced neovascularization, we observed an 11-fold increase in the cornea. Importantly, vascular endothelial growth factor-A-induced chemotaxis of PTK7 + cells was mediated by vascular endothelial growth factor receptor 2. In a coculture with endothelial cells, PTK7 + CD11b + cells stabilized the vascular network for 2 weeks by expressing high levels of angiopoietin-1. The enhanced vascular stability was abolished by knockdown of angiopoietin-1 in PTK7 + CD11b + cells and could be restored by angiopoietin-1 treatment.
A ngiogenesis is a multifactorial process in which different cell types are involved, especially vascular endothelial cells (VECs), pericytes, fibroblasts, and bone marrow (BM)derived cells. [1] [2] [3] A variety of immune cells directly support angiogenesis, including mast cells, tumor-associated macrophages, and Tie2-expressing macrophages. [4] [5] [6] Endothelial cells recruit inflammatory cells to the extravascular tissue because of their expression of different leukocyte adhesion molecules. In turn, immune cells produce soluble factors, such as chemokines, cytokines, and proteases, that bind to endothelial cells and influence their function and angiogenesis in a paracrine fashion. 4 Other studies have shown that BM-derived cells have the ability to differentiate into endothelial cells, possibly by converting first to endothelial progenitors. 6, 7 Interestingly, several lines of evidence suggest the presence of other types of BM-derived circulating progenitor cells that do not incorporate directly into vessel formation, but promote vascular stabilization. 8, 9 These BM-derived perivascular cells interact with and support endothelial cells in the blood vessels, 10, 11 indicating the importance of endothelial progenitor cells (EPCs) and supporting cells to vasculature stabilization. Because the exact cellular markers and functions of these supporting cells and how they are mobilized and recruited into the angiogenic area remain unknown, [12] [13] [14] [15] it is of great interest to characterize circulating progenitor cells and their capacity to support the formation of vascular networks.
The pseudokinase protein tyrosine kinase 7 (PTK7) is an atypical tyrosine kinase receptor that lacks catalytic activity in its kinase domain. 16 PTK7 regulates cell migration polarity, [17] [18] [19] T-cell maturation, migration of BM-derived cells, 20 and endothelial cell migration as well as proliferation during angiogenesis. 21, 22 We have recently provided evidence for an interaction between PTK7 and vascular endothelial growth factor (VEGF) receptor 1 (VEGFR1; Flt-1) leading to enhanced migration of VECs. 22 PTK7 is expressed by circulating mononuclear and leukemic cells and mediates their promigratory and antiapoptotic effects. 20, 23 Moreover, numerous EPC marker studies have highlighted that hematopoietic
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Sunil K. Chauhan,* Hyung Keun Lee,* Hyun Soo Lee, Eun Young Park, Eunae Jeong, Reza Dana (VEGFR1 + ) cells interact with endothelial (VEGFR2 + ) BM-derived progenitor subsets to induce and progress angiogenesis. 7, 24, 25 Although PTK7 is expressed by peripheral blood mononuclear cells (PBMCs) and it interacts with VEGFRs, the specific function of PTK7 + blood cells in angiogenesis has not been thoroughly investigated.
In this study, we examined the role of PTK7 + mononuclear cells in angiogenesis in vitro and in vivo using a VEGF-A micropellet implantation model. We show that BM-derived PTK7 + cells recruited into the cornea in response to VEGF-A are CD11b + mononuclear cells. More importantly, PTK7 + CD11b + mononuclear cells express high levels of VEGFR2 and angiopoietin-1 and are involved in not only neovascularization but also new vessel stabilization.
Materials and Methods
Materials and Methods are available in Supplements I and II in the online-only Data Supplement.
Results

PTK7 + Mononuclear Cells Are Recruited to the Site of New Vessel Formation
The main experiments of this study are schematically illustrated in Figure 1A . To investigate the ingress and localization of PTK7 + cells in the cornea over time, we used an in vivo corneal micropocket angiogenesis model ( Figure 1A ). We found newly formed PECAM-1 + (platelet endothelial cell adhesion molecule, also known as CD31 + ) blood vessels as early as postoperative day 3 after micropellet implantation surgery and a peak vessel growth at 7 days after VEGF-A micropellet implantation (white arrow in Figure 1B , upper). Interestingly, several PTK7 + cells (white arrowhead) localized near the angiogenic area ( Figure 1B , middle). The population of PTK7 + cells peaked on day 2 in the cornea, was maintained until day 5, and then decreased (Supplement III in the online-only Data Supplement). Using confocal microscopy we found that PTK7 + cells were scattered near the vascular branching area, as well as attached to new vessels ( Figure 1C ; white arrows indicate PECAM + cells, white arrowheads indicate PTK7 + cells; and Supplement IV in the online-only Data Supplement). However, most PTK7 + cells, located near the angiogenic area, did not express the VEC marker PECAM-1 and were not incorporated into new vessels ( Figure 1B and 1C; Supplement V in the online-only Data Supplement).
Next, we analyzed PTK7 + cells in the BM, peripheral blood, and cornea in VEGF-A micropellet-implanted mice using flow cytometry. In the BM and peripheral blood PTK7 + frequencies remained similar ( Figure 1D and 1E; P=0.662 for BM and P=0.085 for PBMC; Student t test; Supplement VI in the online-only Data Supplement). But, in the cornea, PTK7 + CD45 + and PTK7 + CD11b + cells were increased significantly 3 and 7 days after stimulation of angiogenesis (P<0.001; Student t test; Figure 1F ), indicating that the PTK7 + cells in the angiogenic area are PTK7 + CD11b + and PTK7 + CD45 + mononuclear cells.
VEGFR2 Upregulation on PTK7 + Cells Promotes VEGF-A-Mediated Cell Migration
VEGFR2 plays a crucial role in vasculogenesis, angiogenesis, and hematopoiesis and is considered as one of the most definitive EPC markers. 26, 27 To address whether the recruitment of PTK7 + cells to the cornea is associated with angiogenesis, we investigated the expression of VEGFR2 on PTK7 + cells during VEGF-A-induced angiogenesis using the corneal micropellet implantation model. Before micropellet implantation (day 0), 0.9% of cells express VEGFR2 in PBMCs, but the frequencies of VEGFR2 + PTK7 + CD11b + cells increased ≈4.6-fold 7 days after VEGF-A pellet implantation (0.9%-4.1% on day 7; Figure 2A ). Interestingly, most of the VEGFR2 + cells were positive for PTK7 + (Figure 2A and 2B). Seven days after micropellet implantation (postoperative day 7), 20.8% of PTK7 + CD11b + cells expressed VEGFR2. But, only 6.1% of PTK7 − CD11b + cells were VEGFR2 + at 7 days after the implantation ( Figure 2B ). The frequencies of VEGFR1 + cells did not differ between PTK7 + CD11b + and PTK7 − CD11b + cells ( Figure 2C ).
Next, we determined VEGFR2 expression of in vitro VEGF-A-stimulated PTK7 + and PTK7 − CD11b + PBMCs using flow cytometry and Western blot. Similar to our in vivo data, VEGFR2 expression was increased only in PTK7 + CD11b + cells but not in PTK7 − CD11b + cells after VEGF-A stimulation ( Figure 2D and 2E). Before in vitro treatment with VEGF-A, the mean frequencies of VEGFR2 + cells among PTK7 − CD11b + and PTK7 + CD11b + cells were 1.1% (0.3%-2.1%) and 2.8% (1.9%-4.5%), respectively (P=0.014, data not shown). However, treatment of VEGF-A for 36 hours increased the VEGFR2 expression to 34.5% in PTK7 + CD11b + cells ( Figure 2D , lower). In PTK7 − CD11b + cells VEGF-A treatment did not change the frequencies of VEGFR2 expression ( Figure 2D , upper). To confirm the role of PTK7 in VEGFR2 induction, PTK7 small interfering RNA (siRNA) was transfected into PTK7 + CD11b + cells, and the expression of VEGFR2 was measured after 24 hours of VEGF-A treatment. Interestingly, VEGF-A-induced VEGFR2 expression in PTK7 + CD11b + cells was reduced when PTK7 was downregulated ( Figure 2E ). In addition, we observed a VEGF-A-dependent VEGFR2 increase in PTK7 + but not PTK7 − cells using Western blot ( Figure 2E and 2F).
To analyze VEGFR2 activity, we measured VEGFR2 receptor phosphorylation in PTK7 + CD11b + cells. Treatment with VEGF-A significantly enhanced VEGFR2 phosphorylation in PTK7 + CD11b + , but not PTK7 − CD11b + cells, in a dosedependent manner ( Figure 2G ). In angiogenesis, VEGFR2 is critical for VEGF-A-mediated chemotaxis of EPCs into the area where the angiogenic process is initiated. 26 Thus, we next analyzed whether VEGF-A treatment of PTK7 + CD11b + cells enhances their migratory potential using a transwell system. VEGF-A treatment significantly increased the migration of PTK7 + CD11b + cells, but not PTK7 − CD11b + cells. At 24 hours after treatment start, there was an 8-fold increase of migration of PTK7 + CD11b + cells compared with PTK7 − CD11b + cells ( Figure 2H ). 
Induction of VEGFR2 Expression on PTK7 + Cells Depends on Nuclear Factor-κB Activation by VEGF-A
We next investigated which signals upregulate VEGFR2 in PTK7 + cells in vitro. We sorted CD11b + PTK7 + and CD11b + PTK7 − cells from PBMCs, treated them with VEGF-A and then analyzed mRNA and protein expression of VEGFR2 ( Figure 3A ). Seven days after micropellet implantation, VEGFR2 mRNA expression was 8.9× higher in PTK7 + CD11b + than in PTK7 − CD11b + cells on in vitro stimulation with 15 ng/mL VEGF-A ( Figure 3B ). Given that PTK7 + cells constitutively express VEGFR1 and regulate VEGFR1 signaling in mononuclear cells, 22 we postulate that PTK7 expression affects VEGFR2 expression through VEGFR1 signaling. Indeed, increased VEGFR2 expression induced by VEGF-A could be inhibited using a VEGFR1 blocking antibody, implying that VEGF-A binding to VEGFR1 mediates VEGFR2 expression in PTK7 + cells ( Figure 3B ). To define the mechanisms underlying PTK7-mediated VEGFR2 upregulation, we used signal transduction inhibitors and evaluated their effect on VEGFR2 mRNA expression in PTK7 + CD11b + cells. Only SN50, a well-known nuclear factor-κB inhibitor, but no other inhibitors, significantly suppressed VEGFR2 mRNA expression ( Figure 3C) . Similarly, VEGFR2 protein expression was inhibited only by SN50 as analyzed via Western blot ( Figure 3D ) and flow cytometry ( Figure 3E ). In addition, RAW-264.7 cells were transfected with PTK7 siRNA, and transcription regulator activities were determined in response to VEGF-A stimulation. Compared with control siRNA, PTK7 siRNA-treated RAW-264.7 cells showed significantly decreased nuclear factor-κB activities ( Figure 3F ) and IκB phosphorylation ( Figure 3G ). These data indicate that VEGF-A activates nuclear factor-κB via VEGFR-1 and thus induces VEGFR-2 expression in PTK7 + cells.
PTK7 + Mononuclear Cells Facilitate Vessel Stabilization In Vitro
Our results showed that PTK7 + mononuclear cells express VEGFR2 and respond to VEGF-A and thus may play a significant role in corneal angiogenesis. We used the matrigel assay to determine the exact role of PTK7 + cells in angiogenesis in vitro. When VECs were cultured alone, the tube-like structures formed at 3 hours and matured at 18 hours, after which the vascular networks began to disappear and simple Y-or T-shaped branch structures remained ( Figure 4A ). When PTK7 − CD11b + cells isolated from micropellet implanted mice were cocultured with VECs, we did not find tube-like structures. Instead, we observed only small cell-to-cell contacts or branch-like structures ( Figure 4A ). Interestingly, VECs that were cocultured with PTK7 + CD11b + cells from micropellet-implanted mice developed tube-like structures, matured in a time-dependent manner, and were stable for 2 weeks ( Figure 4A-4C) .
In Figure 4D , we show VECs cocultured with PTK7 + CD11b + cells from 6 hours to 9 days. Six hours after starting the assay we observed round PBMCs accumulating close to the VECs (Figure 4D , upper left, black box). At 24 hours round PBMCs (upper center, white arrow) gathered closer to VECs (upper right, white arrowhead). Next, networklike structures developed and matured within 72 hours. During the elongation of the vascular network, migratory myeloid cells were found near the vascular network ( Figure 4D , middle row), which were attached to the growing tubes ( Figure 4D , middle right, white arrows). These myeloid-like cells were sometimes linearly attached to each other and were found near the blood vessels ( Figure 4D , middle left, white arrows). This well-formed reticular vascular network was stable for ≤9 days.
To determine whether VEGFR2 expression is able to facilitate tube formation and its stability, we knocked down VEGFR2 in a tube formation assay. After confirming a successful knockdown of VEGFR2 in PTK7 + CD11b + cells by siVEGFR2 transfection (Figure 4E ), we cocultured these cells with VECs as described above. VEC tube formation was significantly reduced when cocultured with siVEGFR2-transfected compared with random siRNA-transfected PTK7 + CD11b + cells ( Figure 4E ). This result confirms that VEGFR2 expression is crucial for vascular network formation.
PTK7 + Mononuclear Cells Enhance Vascular Stability Through ANG-1 Secretion
Based on our previous results, we hypothesized that PTK7 + cells have the potential to stabilize vessel formation. To clarify the specific angiogenic functions of PTK7 + mononuclear cells, we sorted CD11b + PTK7 + and CD11b + PTK7 − cells from PBMCs, BM, or corneas 3 days after micropellet implantation ( Figure 5A ). We first compared mRNA expression of various angiogenic markers in sorted PTK7 − and PTK7 + cells. mRNA expression of vegfr2, angiopoietin-1 (ANG-1), neurophilin 1 (NRP1), apelin (APLN), and δ-like 4 (DLL4) were significantly higher in PTK7 + than in PTK7 − cells ( Figure 5B ). mRNA expression of ang-1 was significantly increased in PTK7 + compared with PTK7 − cells isolated from BM, PBMC, and cornea ( Figure 5C ). Protein expression of ANG-1 was also significantly elevated in PTK7 + cells compared with PTK7 − cells, whereas ANG-2 expression showed no significant difference between PTK7 + and PTK7 − cells ( Figure 5D ). To analyze whether the ANG-1 production of PTK7 + cells needs direct VEC interaction, we used a PTK7 + CD11b + /VEC mixed culture or the Boyden chamber, respectively. ANG-1 secretion from PTK7 + cells ( Figure 5E ) and subsequent phosphorylation of Tie2, a known receptor for ANG-1 ( Figure 5F ), was similar using the mixed culture and Boyden chamber. These observations indicate that the presence of PTK7 itself is responsible for ANG-1 secretion in mononuclear cells. As ANG-1 is a well-known mediator secreted by pericytes to recruit VECs and promote vascular stability, 12,28 PTK7 + cells may stabilize vessel formation via ANG-1 secretion. Thus, we investigated the functional role of ANG-1 in PTK7 + cells. Indeed, PTK7 + CD11b + and VEC cocultures treated with siRNA for ANG-1 displayed less angiogenesis. Moreover, treatment with exogenous ANG-1 protein rescued vascular network formation in a coculture condition with PTK7 knock-downed cells ( Figure 5G ). These data suggest that PTK7 + cells represent a subpopulation of BM-derived mononuclear cells that mediate vascular stabilization through ANG-1 production.
Discussion
In this study, we show that (1) during early angiogenesis, increased frequencies of PTK7 + mononuclear cells are recruited to the angiogenic site, where they closely communicate with VECs and enhance vascular growing and stability; (2) VEGFR2 expression is significantly higher in PTK7 + mononuclear cells than in PTK7cells, and this expression is induced by VEGF-A through VEGFR1-mediated nuclear factor-κB activation; and (3) PTK7 + cells upregulate the expression of the angiogenic mediator ANG-1 and contribute to vascular stability. The main findings of this study are schematically illustrated in Figure 6 .
Although the knowledge about EPCs has increased, the phenotypic and functional characterization of EPCs is hampered by the extreme rarity of these cells, controversial studies on surface marker expression, and the absence July 2015 of standard in vitro or in vivo assays to characterize their function. 29, 30 Nevertheless, EPCs are most commonly identified as CD133 + CD34 + VEGFR2 + , CD45 dim CD34 + VEGFR2 + , CD14 + CD34 low , and CD11b + VEGFR2 + cells. 31 Because VEGFR2 is the only surface marker shared by all studies to identify EPCs, we focused on VEGFR2 expression by PTK7 + mononuclear cells in our study. Moreover, VEGFR2 contributes to angiogenesis and promotes endothelial cell migration and proliferation.
Here, we demonstrate that PTK7 + CD11b + PBMCs express significantly higher amounts of VEGFR2 after angiogenic stimulus. Interestingly, not only CD11b + cells but also F4/80 + PBMCs showed higher PTK7 expression in VEGFR2 + cells than in VEGFR2 -F4/80 + cells (Supplement VII in the onlineonly Data Supplement). PTK7 has previously been shown to interact with VEGFR1 in a VEGF-A-specific manner to enhance angiogenesis in VECs. 22 Ohki et al 32 have reported that CD45 + CD11b + VEGFR1 + cells egress from the BM after injury, and these cells display EPC characteristics. They also found that 50% of the CD11b population expresses VEGFR1, and that these cells show a 5-fold increased revascularization activity, compared with CD11b + VEGFR1cells. Interestingly, we found that most VEGFR2 + CD45 + cells (96.4%) express VEGFR1. In addition, PTK7 + CD11b + cells express higher VEGFR2 levels than PTK7 − CD11b + cells, suggesting that VEGFR1 may be a prerequisite factor for VEGFR2 expression through a PTK7-mediated pathway.
Although splenic PTK7 + and PTK7 − cells express similar amounts of VEGFR2 mRNA, PTK7 + cells in the cornea or blood express significantly increased levels of VEGFR2 compared with PTK7 − cells, which can be further increased by VEGF-A pellet insertion (Supplement VIII in the onlineonly Data Supplement), indicating that VEGFR2 acquisition occurs in a site-specific manner, suggesting that other factors . Cells with hair-like long processes were observed at the end of the blood vessels (white arrows in the middle center and middle right). Macrophage-like cells were linked to growing endothelial buds and the tips of the growing tubes (black box, lower row). A stable vascular network was observed for up to 9 days after culture. E, PTK7 + CD11b + PBMCs were transfected with random small interfering RNA (siRNA [Rsi]) or vascular endothelial cell growth factor receptor (siVEGFR2 [siR2]) and VEGFR2 expression levels were determined by immunoblot at 72 hours after transfection. Then, VEGFR2 knockdown PTK7 + CD11b + cells were cultured with VECs for the tube formation assay. Fourteen days later we observed less tube formation in VECs when cocultured with VEGFR2 knockdown cells.
(eg, neural, neighbor cells, and matrix proteins) also affect the development of EPCs. A recent study demonstrated that VEGFR2 expression promotes EPC egression from the BM into peripheral blood. 13 Stromal cell-derived factor 1/CXCR4 axis disruption induced CD11b + CD45 + BM cell mobilization. [33] [34] [35] However, Pitchford et al 13 reported that VEGF-A activates EPC mobilization through VEGFR2, and not VEGFR1 or the stromal cell-derived factor 1/CXCR4 axis, suggesting that VEGFR2 expression on PTK7 cells in BM EPCs may be critical for EPCs to egress from the BM into peripheral blood.
EPC-induced angiogenesis is a complex process that causes EPCs to migrate to the wound site. We propose that the PTK7 + VEGFR2 + cells we characterized in our study are similar to early-outgrowth cells that are descendants of a monocytemacrophage subset and play a role in blood vessel homeostasis and angiogenesis initiation during wound healing and tissue ischemia. 14, 36 These early-outgrowth cells express CD45 and other mononuclear cell markers (eg, CD11b or CD14), fail to proliferate, and are defined as perivascular cells rather than lumen-lining cells. These cells act by secreting angiogenic factors and enzymes that can degrade the matrix. [37] [38] [39] Similarly, PTK7 + cells primarily express mononuclear cell markers and do not display proliferative activity (data not shown). More importantly, PTK7 + cells are found in and around newly growing blood vessels in a scattered pattern, where they palisade along the growing vessels and aggregate into a blind-ended capillary-like structure. PTK7 + PBMCs express specific pericyte markers, including ANG-1, platelet-derived growth factor (PDGF)-β, and desmin (Supplement IX in the online-only Data Supplement), but not the tip cell marker CD34 ( Figure 5 ). EPHRIN B2) , VEGFR1, unc-5-homolog B (UNC5B), CXCR4, plexin D1 (PLXND1), Neuropilin-2 (NRP-2), and CD34 was done. C, Three days after pellet insertion PTK7 + CD11b + and PTK7 − CD11b + cells were sorted by FACS (fluorescence-activated cell sorting) from the bone marrow (BM), peripheral blood mononuclear cells (PBMC), and cornea. mRNA expression of ANG-1 was assessed using real-time qPCR. The fold increase compared with nonoperated control mice was measured. D, Protein expression of ANG-1 and ANG-2 of in vitro cultured PTK7 − CD11b + and PTK7 + CD11b + cells measured by ELISA after 24 hours of VEGF-A (40 ng/mL) treatment. E and F, A total of 5×10 4 PTK7 + CD11b + cells were cultured with 2×10 5 VECs using a Boyden chamber (BC) or a mixed coculture (MC). ANG-1 protein concentration (E) and phospho-Tie2 and total Tie2 (F) were measured by ELISA or immunoblot, respectively, 24 hours later. G, PTK7 + CD11b + cells were sorted and transfected with random siRNA (Rsi), siRNA for angiopoietin-1 (siANG-1), siANG-2, or siPTK7. Then, cells were cocultured with VECs in a matrigel for 5 days. As indicated 2 coculture conditions of siPTK7-transfected cells and VECs were treated with 40 ng/mL of ANG-1 or ANG-2 every 24 hours. All experiments were repeated 4 times. Data are expressed as the mean±SD. *P<0.05 and **P<0.01.
Because perivascular localized cells, which express ANG-1, platelet-derived growth factor receptor (PDGFR)-β, and CD13, are considered as pericytes, 10,40 PTK7 + cells may function similar to classic pericytes, stabilizing vascular networks by modifying the environment and hence stabilizing tubular structures.
ANG-1 treatment may reduce vascular leakage, inhibit VEC apoptosis, and enhance vascular stability, branching, and remodeling of an immature vessel plexus into a more complex network. 28, [41] [42] [43] ANG-1 expression from BM cells seems to have a critical role in angiogenesis, pericyte recruitment, and vascular stabilization. 12, 28, 44 Our findings show that PTK7 + cells highly express ANG-1 and that the vascular stability of VECs is ANG-1 dependent ( Figure 5 ), suggesting that PTK7 + CD11b + cells supply ANG-1 to the angiogenic area to promote vascularization at an early angiogenic time point.
In summary, this study highlights the relevance of PTK7 expression by mononuclear cells in promoting VEGF-Amediated angiogenesis. Our data suggest that PTK7 amplifies the expression level of VEGFR2 on these cells, which is an important step in the initial phase of angiogenesis. Thus, targeting PTK7 in BM-derived mononuclear cells may provide an effective strategy in treating angiogenesis-related disorders. Figure 6 . Proposed mechanism for the role of Protein tyrosine kinase 7 (PTK7) + vascular endothelial cell growth factor receptor (VEGFR2) + mononuclear cells in angiogenesis. PTK7 expression by mononuclear cells is necessary for VEGFR2 acquisition in bone marrow and peripheral blood. These PTK7 + VEGFR2 + mononuclear cells migrate to angiogenic sites where they promote angiogenesis by upregulating angiopoietin-1 (ANG-1) secretion. Given their topographical localization and expression markers, they likely function in stabilizing blood vessel formation and have endothelial progenitor cell potential. NF-κB indicates nuclear factor-κB.
